In January 2025, the EU HTA Regulation will become a reality: all new cancer medicines and advanced therapy medicinal products (ATMPs) will be jointly assessed at the EU level.

The new EU HTA presents a significant opportunity for Europe to speed up access to new treatments. But only if we find  a workable solution for a truly European assessment of the best available evidence, which can facilitate national decisions on access for these innovations. 

A recent report commissioned by the EFPIA Oncology Platform simulated the new joint clinical assessment on three cancer medicines that were approved in recent years. It shows that the proposed methods do not always fit the specificities of medicines for cancer and novel therapies that use genes, tissues and cells. If applied from 2025, this approach would hamper access to some of the most cutting-edge products in the research pipeline.

As the clock ticks toward 2025, join us for a discussion on how we can work together to ensure that EU HTA can facilitate faster access for patients and not be an additional barrier. 

Speakers:
- Antonella CARDONE - CEO, Cancer Patients Europe
- Robin DOESWIJK - Head of European Affairs, European Hematology Association
- Tanja PODKONJAK - Head of Access Intelligence and Readiness, Takeda